Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guselkumab versus continued ustekinumab in plaque psoriasis with inadequate response to ustekinumab
2014-000721-20Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in plaque psoriasis and psoriasis comparing Switch to guselkumab with Continue ustekinumab (2 arms). Primary endpoint: Number of visits with IGA response from Week 28 through Week 40. Started Aug 2014; status: completed.
02
Drugs
guselkumabustekinumab
03
Conditions
plaque psoriasispsoriasis
Beyond the preview
Go deeper on 2014-000721-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000721-20.